Literature DB >> 1981751

Imidazoline receptors in rat liver cells: a novel receptor or a subtype of alpha 2-adrenoceptors?

R Zonnenchein1, S Diamant, D Atlas.   

Abstract

An imidazoline/guanidine receptor has been characterized in rat liver cells. Binding of [3H]idazoxan, a selective benzodioxan antagonist, to imidazoline receptor on intact fresh hepatocytes (Bmax = 801 +/- 23 fmol/mg protein, Kd = 11 +/- 0.8 nM) and to liver membranes (Bmax = 400 +/- 38 fmol/mg protein, Kd = 10 +/- 2 nM) was saturable at 4 degrees C within 3.5 h and at 30 degrees C within 30 min, respectively. Rat lung membranes had more imidazoline sites (Bmax = 578 +/- 30 fmol/mg protein, Kd = 14 +/- 1.4 nM) than alpha 2-adrenoceptors (Bmax = 175.0 +/- 20.0 fmol/mg protein, Kd = 4.8 +/- 2.0 nM). We also screened other tissues for imidazoline sites; the ratio of adrenoceptors to total sites labeled with [3H]idazoxan displaced by cirazoline was lower in rat lung compared to rat brain and human platelets. The imidazoline receptor has common pharmacological properties with alpha 2-adrenoceptors, although it is not a subtype of the adrenoceptor, since it bound neither the endogenous agonists norepinephrine and epinephrine, nor the selective alpha 2-antagonists yohimbine and phentolamine. All guanidine type alpha 2-adrenoceptor drugs (e.g. guanbenz, guanoxan) and imidazolines (e.g., UK-14,304, naphazoline) competed with high affinity for the liver imidazoline receptor. The lack of effect by Gpp(NH)p, a non-hydrolysable GTP analogue, on the affinity of guanidine- and imidazoline-type ligands for liver imidazoline receptors suggests that the mode of action of these drugs at imidazoline receptors is different than at conventional alpha 2-adrenoceptors. Ionic changes were considered as a possible mechanism underlying the alpha 2-adrenoceptor effects in various cells. Opening of K+ channels by alpha 2-adrenoceptors agonists is a pathway which might be shared by imidazoline-type agonists at imidazoline sites. Indeed, 4-aminopyridine, a K+ channel blocker, inhibited the specific binding of [3H]idazoxan to liver cells with an IC50 of 0.34 +/- 0.07 mM a concentration which is effective in blocking K+ channels in neuronal cells. Similarly, Cs+ and NH4+ effectively interfered with [3H]idazoxan binding, suggesting a possible coupling of imidazoline sites to K+ gating. The endogenous ligand clonidine-displacing substance (CDS), which was isolated from bovine brain and which binds to alpha 2-adrenoceptors in brain membranes and human platelets competed with idazoxan at rat liver imidazoline receptors.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1981751     DOI: 10.1016/0014-2999(90)94127-j

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  15 in total

1.  Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X.

Authors:  Rodney A Velliquette; Rachel Kossover; Stephen F Previs; Paul Ernsberger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-01-17       Impact factor: 3.000

2.  Activation of I(2)-imidazoline receptors enhances supraspinal morphine analgesia in mice: a model to detect agonist and antagonist activities at these receptors.

Authors:  P Sánchez-Blázquez; M A Boronat; G Olmos; J A García-Sevilla; J Garzón
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

3.  The effects of chronic imidazoline drug treatment on glial fibrillary acidic protein concentrations in rat brain.

Authors:  G Olmos; R Alemany; P V Escriba; J A García-Sevilla
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

4.  Inhibitory presynaptic imidazoline receptors on sympathetic nerves in the rabbit aorta differ from I1- and I2-imidazoline binding sites.

Authors:  G J Molderings; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-05       Impact factor: 3.000

5.  Species-selective binding of [3H]-idazoxan to alpha 2-adrenoceptors and non-adrenoceptor, imidazoline binding sites in the central nervous system.

Authors:  J F Hussain; D A Kendall; V G Wilson
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

6.  Relevance of the use of [3H]-clonidine to identify imidazoline receptors in the rabbit brainstem.

Authors:  G Bricca; J Zhang; H Greney; M Dontenwill; J Stutzmann; A Belcourt; P Bousquet
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

7.  Antagonism of levcromakalim by imidazoline- and guanidine-derivatives in rat portal vein: involvement of the delayed rectifier.

Authors:  T Ibbotson; G Edwards; A H Weston
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

8.  Stimulation of insulin secretion by imidazoline compounds is not due to interaction with non-adrenoceptor idazoxan binding sites.

Authors:  C A Brown; A C Loweth; S A Smith; N G Morgan
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

9.  RS-45041-190: a selective, high-affinity ligand for I2 imidazoline receptors.

Authors:  C M Brown; A C MacKinnon; W S Redfern; A Williams; C Linton; M Stewart; R U Clague; R Clark; M Spedding
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

10.  Imidazoline binding sites in human placenta: evidence for heterogeneity and a search for physiological function.

Authors:  S Diamant; T Eldar-Geva; D Atlas
Journal:  Br J Pharmacol       Date:  1992-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.